Search NXTS
Nexentis Technologies Inc.
Nasdaq · CIK 1789192
Last close1.49
Daily change+0.06 (4.20%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NXTS · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
42.8Momentum
n/aAcceleration
n/aConfidence
76.0Annual Revenue7
Quarterly Revenue25
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality7.7 / 25
Capital Efficiency8.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 111.8087 percentage points.
Key Metrics
Revenue Growth TTM-53.72%OK
Revenue CAGR 3Y-21.74%OK
Gross Margin-23.38%OK
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | n/a | -$4.23M | -$3.81M | -$3.82M | n/a | n/a | n/a | n/a | 1.29M |
| 2025 FY Dec 31, 2024 | n/a | n/a | -$3.28M | -$3.42M | n/a | n/a | n/a | n/a | n/a | 187,215 |
| 2024 FY Dec 31, 2024 | $210,000.00 | $45,000.00 | n/a | n/a | n/a | 21.43% | n/a | n/a | n/a | n/a |
| 2024 FY Dec 31, 2023 | $263,000.00 | $208,000.00 | -$7.58M | -$3.23M | n/a | 79.09% | -2,881.37% | n/a | -549.57% | 1.2M |
| 2023 FY Dec 31, 2022 | $394,004.00 | $235,691.00 | -$5.82M | -$5.10M | -$5.15M | 59.82% | -1,477.05% | -1,306.79% | n/a | 528,776 |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $77,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0001493152-25-022355, 0001641172-25-010883 |
| Revenue Growth TTM | -53.72% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-25-022355, 0001641172-25-010883 |
| Revenue CAGR 3Y | -21.74% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001641172-25-001513 |
| Revenue CAGR 5Y | 3.62% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001641172-25-001513 |
| Gross Profit CAGR 3Y | -47% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001641172-25-001513 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | -23.38% | Gross Profit / Revenue | OK | 0001493152-25-022355, 0001641172-25-010883 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-25-022355 |
| Current Ratio | 4.21x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 5.13x | (Cash + Short-term Investments) / Total Debt | OK | 0001493152-25-022355 |
| Revenue per Diluted Share | $0.08 | Revenue / Diluted Shares | OK | 0001493152-25-022355, 0001641172-25-010883 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | derived |